Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Decaffeinated Coffee Might Boost Brain Power for Type 2 Diabetes

Decaf coffee was found to improve glucose energy metabolism in the brain in mouse studies....

Advertisement

Type 2 diabetes is linked to cognitive decline, dementia and Alzheimer's disease that stems from impaired breakdown of glucose needed for optimal brain function. The study is the first to show decaffeinated coffee might prevent and treat declining memory associated with Type 2 diabetes, aging and neurodegenerative disorders.

For the study researchers gave mice induced to develop diabetes a decaf coffee supplement for five months and then evaluated the mouse brain's genetic response to the treatment. The result was increased ability of the brain to metabolize glucose.

Giulio Maria Pasinetti, MD, PhD, Professor of Neurology, and Psychiatry, at Mount Sinai School of Medicine, said it's important to find ways to prevent cognitive decline from neurodegenerative diseases. Studies show pathological changes in the brain occur decades before Alzheimer's and other diseases develop. He also notes the study shows not all of the health benefits associated with coffee come from caffeine.

It's important to note that coffee can have negative cardiovascular effects and is linked to elevated blood pressure and cholesterol levels, making consumption risky for some.

Pasinetti plans to explore whether decaffeinated coffee could be useful as a dietary supplement in humans to prevent or even treat memory loss associated with Type 2 diabetes and other brain disorders.

Nutritional Neuroscience H. Lap et al.Nov. 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2012 and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Past five issues: Diabetes Clinical Mastery Series Issue 216 | Issue 756 | Diabetes Clinical Mastery Series Issue 215 | SGLT-2 Inhibitors Special Edition November 2014 | Issue 755 |

2014 Most Popular Articles:

New SGLT2 Inhibitor Likely To Be Approved for Type 2 Diabetes
Posted November 14, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014
Grapefruit Juice May Affect Insulin Resistance
Posted October 23, 2014
Very Low Carbohydrate, Low Saturated Fat Diet for Type 2 Diabetes Management
Posted November 07, 2014
Dietary Magnesium Intake's Role in Decreasing Metabolic Syndrome
Posted October 31, 2014
Exercise Promotes Preservation of Beta Cells
Posted November 14, 2014
Handbook of Diabetes, 4th Ed., Excerpt #16: Diabetic Neuropathy
Posted November 02, 2014
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-dose Combination
Posted October 23, 2014
What's Hiding in that Insulin Box?
Posted October 27, 2014
Interview with NuSirt CEO Joe Cook, Jr: Improving Metformin Treatment, Part 1
Posted November 02, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
If the U.S. Affordable Care Act is reversed in the new congress, what impact will that have on your patients?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control